Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Therapeutic vaccine | 1 |
Top 5 Target | Count |
---|---|
APP(Beta amyloid A4 protein) | 1 |
Target |
Mechanism APP inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDE7 inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism APP inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date13 Dec 2017 |
Sponsor / Collaborator |
Start Date01 Jan 2014 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
ABvac-40 ( APP ) | Alzheimer Disease More | Phase 2 |
ABvac-42 ( APP ) | Alzheimer Disease More | Pending |
S-14 ( PDE7 ) | Parkinson Disease More | Pending |